Clinical Trial Update: A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports the termination of a Phase 1/2 study evaluating intraperitoneal EGEN-001 alone and in combination with standard chemotherapy for color…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Peritoneal Carcinomatosis

Drugs mentioned

• EGEN-001

Snippet

Sponsor: EGEN, Inc. | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: TERMINATED